---
title: "免疫系统的"交通管制"：Treg细胞如何与内皮细胞"对话"？"
date: 2025-04-27T00:22:03Z
draft: ["false"]
tags: [
  "fetched",
  "今日病理"
]
categories: ["Acdemic"]
---
免疫系统的"交通管制"：Treg细胞如何与内皮细胞"对话"？ by 今日病理
------
<div><p><span leaf=""><span textstyle="">最新一期 </span><span textstyle="">Nature Reviews Immunology</span><span textstyle=""> 上，美国马里兰大学Jonathan S. Bromberg教授团队发表重磅综述，系统解析</span><span textstyle="">了</span><span textstyle="">Treg如何像"交警"一样，在血管和淋巴管的"收费站"（内皮细胞）调控下，决定免疫反应的走向</span><span textstyle="">。这项研究不仅为肿瘤免疫治疗耐药性提供了新解释，还为自身免疫病、器官移植排斥等难题开辟了新思路。</span></span></p><p><span leaf=""><img data-backh="224" data-backw="554" data-ratio="0.4054726368159204" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z47mUkpmicJQrQw2gyQic1ibpwYFbzElLiaJOVBsZicFxqhjWJjwO9cq5JwjQ/640?wx_fmt=png" data-w="1206" src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z47mUkpmicJQrQw2gyQic1ibpwYFbzElLiaJOVBsZicFxqhjWJjwO9cq5JwjQ/640?wx_fmt=png"></span></p><p><span leaf=""><span textstyle="">肿瘤治疗：</span><span textstyle="">PD-1抑制剂为何对部分患者无效？可能是Treg细胞在肿瘤里</span></span></p><p><span leaf=""><span textstyle="">国自然热点：</span><span textstyle="">与"免疫微环境动态调控"、"代谢-免疫互作"等优先领域高度契合</span></span></p><p><span leaf=""><span textstyle="">临床转化：已有药企基于该研究开发新一代免疫联合疗法</span></span></p><p><span leaf=""><span textstyle="">Treg巡逻路线：</span><span textstyle="">血液→组织→淋巴结→淋巴管→血液</span><span textstyle="">。 </span></span></p><p><span leaf=""><span textstyle="">Treg的迁移路线图  </span></span></p><p><span leaf=""><span textstyle="">a血液→淋巴结迁移：通过高内皮微静脉进入淋巴结。</span><span textstyle="">关键分子：</span><span textstyle="">CCR7/CCL21、CD62L-GLYCAM1相互作用。</span><span textstyle="">特点：在稳态和炎症条件下均持续发生。</span></span></p><p><span leaf=""><span textstyle="">b组织→淋巴管迁移：90%通过旁细胞途径穿越淋巴管内皮。</span><span textstyle="">关键调控：</span><span textstyle="">LTα1β2-LTβR信号降低血管内皮钙黏蛋白表达，PD-1—PD-L1激活PI3K-AKT通路，S1P-S1PR1引导迁移方向</span><span textstyle="">。特点：炎症时迁移增强，Treg表型发生改变。</span></span></p><p><span leaf=""><span textstyle="">c淋巴管→血液回归：</span><span textstyle="">通过胸导管进入血液循环 依赖S1P浓度梯度引导  特点：完成免疫监视循环。</span></span></p><p><span leaf=""><span textstyle="">该迁移路线图创新性地将Treg在血管、组织和淋巴管中的动态行为整合为一个完整的循环过程，并阐明不同区室的特异性调控机制。</span></span><page></page></p><p><span leaf=""><img data-backh="388" data-backw="403" data-ratio="0.9621409921671018" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4A0gJOpVkO29RCsPFjfO9vtUPLiaVD9G7mJaKbeNy6mPS6jac05uzePg/640?wx_fmt=png" data-w="766" src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4A0gJOpVkO29RCsPFjfO9vtUPLiaVD9G7mJaKbeNy6mPS6jac05uzePg/640?wx_fmt=png"></span></p><p><p><span leaf=""><span textstyle=""> 图1 | Treg通过与内皮细胞的直接相互作用进行运输</span></span></p></p><p><span leaf=""><span textstyle="">内皮细胞如何与Treg对话？</span></span></p><p><span></span><page></page></p><table><tbody><tr><td data-colwidth="79" width="79" valign="top"><p><span leaf=""><span textstyle="">调控方式</span></span><span></span></p></td><td data-colwidth="139" width="139" valign="top"><p><span leaf=""><span textstyle="">关键分子</span></span><span></span></p></td><td data-colwidth="197" width="197" valign="top"><p><span leaf=""><span textstyle="">对Treg的影响</span></span><span></span></p></td><td data-colwidth="152" width="152" valign="top"><p><span leaf=""><span textstyle="">治疗靶点</span></span><span></span></p></td></tr><tr><td data-colwidth="79" width="79" valign="top"><p><span leaf=""><span textstyle="">功能维持</span></span><span></span></p></td><td data-colwidth="139" width="139" valign="top"><p><span leaf=""><span textstyle="">PD-L1, TGF-β</span></span><span></span></p></td><td data-colwidth="197" width="197" valign="top"><p><span leaf=""><span textstyle="">稳定FOXP3，增强抑制性</span></span><span></span></p></td><td data-colwidth="152" width="152" valign="top"><p><span leaf=""><span textstyle="">抗PD-1/PD-L1疗法</span></span><span></span></p></td></tr><tr><td data-colwidth="79" width="79" valign="top"><p><span leaf=""><span textstyle="">促炎转化</span></span><span></span></p></td><td data-colwidth="139" width="139" valign="top"><p><span leaf=""><span textstyle="">IL-6, HIF-1α</span></span><span></span></p></td><td data-colwidth="197" width="197" valign="top"><p><span leaf=""><span textstyle="">诱导exTreg，促炎症或抗肿瘤</span></span><span></span></p></td><td data-colwidth="152" width="152" valign="top"><p><span leaf=""><span textstyle="">IL-6抑制剂（如托珠单抗）</span></span><span></span></p></td></tr><tr><td data-colwidth="79" width="79" valign="top"><p><span leaf=""><span textstyle="">代谢操控</span></span><span></span></p></td><td data-colwidth="139" width="139" valign="top"><p><span lang="EN-US"><span leaf=""><span textstyle="">乳酸, S1P</span></span><span leaf=""><span textstyle="">      </span></span></span><span></span></p></td><td data-colwidth="197" width="197" valign="top"><p><span leaf=""><span textstyle="">提供能量，维持存活</span></span><span></span></p></td><td data-colwidth="152" width="152" valign="top"><p><span leaf=""><span textstyle="">MCT1/S1PR1抑制剂</span></span></p><p><p><span leaf=""><span textstyle=""> </span></span></p></p></td></tr><tr><td data-colwidth="79" width="79" valign="top"><p><span leaf=""><span textstyle="">抗原调控</span></span><span></span></p></td><td data-colwidth="139" width="139" valign="top"><p><span lang="EN-US"><span leaf=""><span textstyle="">MHC-II, OX40L</span></span><span leaf=""><span textstyle="">      </span></span></span><span></span></p></td><td data-colwidth="197" width="197" valign="top"><p><span leaf=""><span textstyle="">决定Treg活化或凋亡</span></span><span></span></p></td><td data-colwidth="152" width="152" valign="top"><p><span leaf=""><span textstyle="">共刺激分子阻断剂</span></span><span></span></p></td></tr></tbody></table><p><p><span leaf=""><br></span></p></p><p><span leaf=""><span textstyle="">1-维持Treg的"警察身份"（免疫抑制功能）</span><span textstyle="">核心机制：PD-1/PD-L1信号轴。作用：内皮细胞（尤其是淋巴管内皮LEC）高表达PD-L1，通过结合Treg表面的PD-1：稳定FOXP3表达：防止Treg失去抑制性。增强迁移能力：激活PI3K-AKT通路，帮助Treg穿越内皮屏障。临床意义：肿瘤中PD-L1高的血管可能"圈养"Treg，导致免疫治疗耐药。抗PD-1疗法可能让Treg滞留肿瘤，同时削弱其抑制功能。其他关键分子：CD39/腺苷通路：Treg通过CD39产生腺苷，抑制局部炎症，同时反馈增强内皮屏障功能。TGF-β：内皮分泌的TGF-β可促进初始T细胞转化为Treg。</span></span></p><p><span leaf=""><img data-backh="498" data-backw="375" data-ratio="1.328" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z42b6volp9uUAzdKCqXO6PR5xc8TTCCE36uGCCYpdkUQbPCZQ9nzCib2Q/640?wx_fmt=png" data-w="375" src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z42b6volp9uUAzdKCqXO6PR5xc8TTCCE36uGCCYpdkUQbPCZQ9nzCib2Q/640?wx_fmt=png"></span></p><p><span leaf=""><span textstyle="">图2| PD1和PDL1在Treg细胞迁移中的作用</span></span></p><p><span leaf=""><span textstyle="">2-让Treg"变坏"（促炎转化）</span><span textstyle="">核心机制：炎症因子重编程。IL-6的颠覆作用：炎症状态下，内皮细胞分泌IL-6，诱导Treg失去FOXP3，转化为促炎性exTreg（分泌IFN-γ）。后果：可能加剧自身免疫病，但在肿瘤中或能"策反"Treg攻击癌细胞（见Fig.6）。缺氧环境：肿瘤内皮低氧上调HIF-1α，迫使Treg转向糖酵解代谢，增强其存活和抑制功能。临床意义：阻断IL-6（如托珠单抗）或靶向HIF-1α，可能逆转Treg的免疫抑制。</span></span></p><p><span leaf=""><img data-backh="505" data-backw="553" data-ratio="0.9131578947368421" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4Gic6pQsbVGLqB6Tk2miaZ7mFNhrdNvYZ2DHUoY9wfTMK0QgjMS7WoF9A/640?wx_fmt=png" data-w="760" src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4Gic6pQsbVGLqB6Tk2miaZ7mFNhrdNvYZ2DHUoY9wfTMK0QgjMS7WoF9A/640?wx_fmt=png"></span></p><p><span leaf=""><span textstyle="">图</span></span><span leaf=""><span textstyle="">3</span></span><span leaf=""><span textstyle="">|内皮细胞直接影响Treg细胞功能和稳定性</span></span></p><p><span leaf=""><span textstyle="">3-代谢调控：Treg的"能量补给站" </span><span textstyle="">内皮细胞通过代谢物"投喂"Treg：乳酸：肿瘤内皮高分泌乳酸，Treg通过MCT1摄取，维持抑制功能。S1P：淋巴管内皮释放S1P，激活Treg的S1PR1，促进其迁移和存活。干预策略：抑制乳酸转运体（MCT1/4）或S1P合成酶（SPHK2），可削弱Treg的肿瘤浸润。</span></span></p><p><span leaf=""><img data-backh="510" data-backw="514" data-ratio="0.9922178988326849" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4BHyXeiaDdbkXyAOH4mXjVRic0WMsDhvL3AOOq5lPAZMyvXxHmdLbwpKg/640?wx_fmt=png" data-w="514" src="https://mmbiz.qpic.cn/sz_mmbiz_png/hicCwtwDKUYEWQr3nlDZkTOPDTs5851Z4BHyXeiaDdbkXyAOH4mXjVRic0WMsDhvL3AOOq5lPAZMyvXxHmdLbwpKg/640?wx_fmt=png"></span></p><p><span leaf=""><span textstyle="">图</span></span><span leaf=""><span textstyle="">4</span></span><span leaf=""><span textstyle=""> | S1P和S1PRs在Treg细胞迁移中的作用</span></span></p><p><span leaf=""><span textstyle="">4-抗原呈递：内皮细胞的"身份核查"  </span><span textstyle="">MHC-II分子：内皮细胞可向Treg呈递抗原，直接调控其活化（尤其在移植器官中）。共刺激分子（OX40L/ICOSL）：决定Treg是增殖、凋亡还是耐受。</span></span></p><p><span leaf=""><span textstyle="">这篇综述的</span><span textstyle="">创新性</span><span textstyle="">在于</span><span textstyle="">首次系统性地描绘了Treg细胞在体内的完整迁移路径及其调控机制</span><span textstyle="">。与以往研究不同，它不仅分析了Treg在血管、组织或淋巴管等特定部位的静态特征，更重要的是</span><span textstyle="">阐明了Treg从血液历经组织、淋巴管再回到血液这一动态过程中的功能变化。</span><span textstyle="">研究发现，在不同解剖部位，Treg会与局部内皮细胞通过特定分子发生互作，从而获得不同的表型和功能特征。这种将细胞迁移轨迹与功能调控相结合的研究思路，为开发靶向Treg迁移的免疫治疗策略提供了新的理论基础。同时，</span><span textstyle="">这种"动态+整合"的研究思路值得在综述写作中借鉴。</span></span><page></page></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/d86GYH6WhqthemLThyHHkQ",target="_blank" rel="noopener noreferrer">原文链接</a>
